beta

ADTX

ADiTx Therapeutics, Inc.

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

ADiTx Therapeutics, Inc. is a preclinical stage, life sciences company which engages in the development of nucleic acid (DNA)-based technologies to minimize rejection of transplanted organs by human recipients as well as address autoimmune diseases and allergies. The firm have worldwide license for commercializing a nucleic acid-based technology, named Apoptotic DNA Immunotherapy (ADi), which utilizes a novel approach that mimics the way the body naturally induces tolerance to its own tissue. The company was founded by Leonard L. Bailey, Shahrokh Shabahang, and Amro Albanna on September 28, 2017 and is headquartered in Loma Linda, CA.

Market Cap: 30.7 Million

Primary Exchange: NASDAQ

Website: http://www.aditxt.com

Shares Outstanding: 5.17 Million

Float: 1.1 Million

Dividend: (%)

Beta: -3.29927997802116

Sector: Health Technology

Industry: Biotechnology

Ethical Flags

Longest drawdown: 16 trading days

From: 2020-07-01 To: 2020-07-24

Lowest Point:

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud